stonks4u
Sign up free
RXRX logo

RXRX Recursion Pharmaceuticals, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$3.16
-0.15 (-4.53%)

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-s…

Market Cap: $1.66Bwww.recursion.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

120
7388104120
Aug 10Aug 11

Quote

Day Range
$3.14 – $3.31
52-Week Range
$2.77 – $7.18
Volume
$10.46M
Market Cap
$1.66B
50-Day Avg
$3.29
200-Day Avg
$3.76
Prev Close
$3.31
Open
$3.30

Valuation & Ratios

P/E Ratio
-2.84
EPS
$-1.44
P/B Ratio
1.62
P/S Ratio
24.50
Debt/Equity
0.07
Current Ratio
5.50
Dividend Yield
+0.0%
Gross Margin
-62.0%

Returns & Efficiency

Return on Equity
-57.0%
Return on Assets
-43.7%
FCF Yield
-20.7%
EV/EBITDA
-2.08

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$74.68M$-644.76M$-1.44
2024$58.84M$-463.66M$-1.69
2023$43.88M$-328.07M$-1.58
2022$39.68M$-239.48M$-1.36
2021$10.00M$-186.48M$-1.05

Social Signal Score

47
5d
47
2 mentions
—
30d
47
2 mentions
—
60d
47
2 mentions
—
90d
47
2 mentions
—
news: 2

Earnings

Wed, Nov 4(in 3 months)

Consensus estimate $-0.22 per share

3of 7 quarters beat consensus

Typical surprise -4.2% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, Aug 5$-0.25 vs $-0.24miss
  • Wed, May 6$-0.22 vs $-0.30beat
  • Wed, Feb 25$-0.21 vs $-0.28beat
  • Wed, Nov 5$-0.36 vs $-0.38beat
  • Tue, Aug 5$-0.41 vs $-0.35miss
  • Mon, May 5$-0.50 vs $-0.44miss

Estimates and results for RXRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

RXRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (2)

  • Newsseekingalpha.com·3d ago·Positive

    Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript

    View source ↗
  • Newsseekingalpha.com·4d ago·Negative

    Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and Sanofi, have delivered $500M+ in milestone payments, but further commercial validation is pending. The internal pipeline, led by REC-4881 for FAP, potentially lags competitors (more data is required) and is unlikely to generat

    View source ↗